Journal article

The application of theranostics in different stages of prostate cancer

Omar Alghazo, Renu Eapen, Samantha Koschel, Marcus Cumberbatch, James Buteau, Rebecca Loh, Nathan Lawrentschuk, Declan G Murphy

FUTURE ONCOLOGY | FUTURE MEDICINE LTD | Published : 2021

Abstract

Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. The most studied radioligand is 177Lu-PSMA-617, which targets PSMA, a protein found in prostate cancer cells. This new approach has shown promising results in treating metastatic castration-resistant prostate cancer. Currently, many trials are using PSMA-targeting radioligands in combination with conventional therapies in advanced prostate cancer or even in ..

View full abstract